308 related articles for article (PubMed ID: 19618185)
1. Killer dendritic cells and their potential for cancer immunotherapy.
Larmonier N; Fraszczak J; Lakomy D; Bonnotte B; Katsanis E
Cancer Immunol Immunother; 2010 Jan; 59(1):1-11. PubMed ID: 19618185
[TBL] [Abstract][Full Text] [Related]
2. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.
Wesa AK; Storkus WJ
Cell Death Differ; 2008 Jan; 15(1):51-7. PubMed ID: 17948028
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.
Hanke N; Alizadeh D; Katsanis E; Larmonier N
Crit Rev Immunol; 2013; 33(1):1-21. PubMed ID: 23510023
[TBL] [Abstract][Full Text] [Related]
4. Killer dendritic cells and their potential role in immunotherapy.
Ullrich E; Chaput N; Zitvogel L
Horm Metab Res; 2008 Feb; 40(2):75-81. PubMed ID: 18283624
[TBL] [Abstract][Full Text] [Related]
5. [Role of dendritic cells in the modulation of innate effectors of immunity].
Terme M; Masurier C; Fernandez N; Lacassagne MN; Marolleau JP; Zitvogel L
Pathol Biol (Paris); 2001 Jul; 49(6):475-7. PubMed ID: 11484608
[TBL] [Abstract][Full Text] [Related]
6. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.
Mailliard RB; Son YI; Redlinger R; Coates PT; Giermasz A; Morel PA; Storkus WJ; Kalinski P
J Immunol; 2003 Sep; 171(5):2366-73. PubMed ID: 12928383
[TBL] [Abstract][Full Text] [Related]
8. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
9. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
10. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
[TBL] [Abstract][Full Text] [Related]
11. The 'kiss of death' by dendritic cells to cancer cells.
Chan CW; Housseau F
Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
[TBL] [Abstract][Full Text] [Related]
13. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
16. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines.
Kalinski P; Nakamura Y; Watchmaker P; Giermasz A; Muthuswamy R; Mailliard RB
Immunol Res; 2006; 36(1-3):137-46. PubMed ID: 17337774
[TBL] [Abstract][Full Text] [Related]
17. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
[TBL] [Abstract][Full Text] [Related]
18. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
Front Immunol; 2020; 11():631713. PubMed ID: 33679726
[TBL] [Abstract][Full Text] [Related]
19. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
[TBL] [Abstract][Full Text] [Related]
20. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]